Artiva Biotherapeutics is preparing to release near-term data readouts from its unmodified, preserved natural killer (NK) cell product candidate targeting autoimmune disease. This program is designed to overcome supply and safety challenges associated with CAR T-cell therapies by providing an off-the-shelf solution. Early clinical results in relapsed or refractory B-cell lymphoma have demonstrated evidence of target engagement and preliminary activity, with reduction in circulating malignant B-cell counts observed in a majority of evaluable patients. Management has guided for autoimmune trial data to be presented at a major immunology conference in the coming quarter, a catalyst that could shift the company from relative obscurity to heightened investor focus.

A tally of six research firms covering Artiva Biotherapeutics yields a consensus recommendation of Moderate Buy. Coverage breakdown includes one sell rating, four buy ratings and one strong-buy rating, with an average twelve-month price objective of $19.00 per share. Recent analyst actions include: Weiss Ratings reiterating a sell (d-) rating; Jefferies Financial Group upgrading to strong-buy; HC Wainwright raising its target from $12.00 to $15.00; Wedbush lifting its objective from $18.00 to $23.00; and Needham & Company reaffirming a buy rating with an $18.00 target. These revisions reflect growing confidence in Artiva’s clinical progress and platform scalability.

CEO Fred Aslan sold 25,500 shares for total proceeds of $153,000, reducing his direct stake to 356,721 shares valued at approximately $2.14 million, representing a 6.7% ownership decrease. Over the past ninety days, insiders have divested 35,062 shares for aggregate proceeds of $193,670, and corporate insiders currently hold 21.4% of outstanding shares. On the institutional front, Ground Swell Capital initiated a position with a $38,000 investment in Q2, Prelude Capital Management added $41,000 in Q3, and Bridgeway Capital Management committed $53,000 in Q2. Bank of America more than tripled its stake to 16,145 shares (a $46,000 holding) by acquiring an additional 11,190 shares, while Y Intercept Hong Kong entered with a $48,000 position in Q2.